darzalex™ 100mg/5ml
5 ml glass vial -
darzalex™ 400 mg/20 ml
20 ml glass vial -
darzalex 20 mg/ml concentrate for solution for infusion (iv)
johnson & johnson (phils.), inc. - daratumumab - concentrate for solution for infusion (iv) - 20 mg/ml
darzalex 20 mg/ml concentrate for solution for infusion (iv)
johnson & johnson (phils.), inc. - daratumumab - concentrate for solution for infusion (iv) - 20 mg/ml
darzalex® 1,800mg 1,800 mg (120 mg per ml) injection
modern pharmaceutical company switzerland - 1 glass vial (15 ml) - injection - 1,800 mg (120 mg per ml) - malignant disease,immunosuppresion-cytotoxics
darzalex™ 100mg/5ml 20 mg/ml infusion
modern pharmaceutical company switzerland - 5 ml glass vial - infusion - 20 mg/ml - malignant disease,immunosuppresion-cytotoxics
darzalex™ 400 mg/20 ml 20 mg/ml infusion
modern pharmaceutical company switzerland - 20 ml glass vial - infusion - 20 mg/ml - malignant disease,immunosuppresion-cytotoxics
darzalex 1800 mg per 15 ml solution for injection
janssen pharmaceutica n.v, belgium - daratumumab - solution for injection - 1800 mg
darzalex sc 1,800 mg/15 ml (120 mg/ml) solution for injection (sc)
n/a; importer: johnson & johnson (philippines), inc.; distributor: johnson & johnson (philippines), inc. - daratumumab - solution for injection (sc) - 1,800 mg/15 ml (120 mg/ml)
darzalex 100 mg per 5 ml concentrate for solution for infusion
janssen pharmaceutica n.v, belgium - daratumumab - concentrate for solution for infusion - 20 mg/ml